Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Scientists use a specific type of cell called haematopoietic stem cells, which produce all types of blood cells, including ...

SEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, (GLOBE NEWSWIRE) --  Adaptive ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...